A Phase 2 interventional study of LYT-100 BCRL and Placebo BCRL in Breast Cancer Related Lymphoedema and Lymphoedema, sponsored by PureTech. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by PureTech · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Lymphedema with a site in United States — 37 open to participants now, 45 under way, 1 of them phase 3. Lymphedema · United States.
Among the 168 studies in Lymphedema with a site in United States, this one is the 60th largest by enrollment of the 122 interventional ones that give a count, is one of 10 that started in 2020, is one of 19 in phase 2, and was the 107th registered.
529 studies on the registry are indexed under Lymphedema; 130 are open to participants now.
Browse Lymphedema studies →37 of the 168 studies in Lymphedema with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
Tactile Medical · Sites in United States
Ages 18+
University Hospital, Basel, Switzerland · Sites in United States, Austria, Canada and 8 more countries
Ages 18+
University of South Florida · Sites in United States
Ages 18–75 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 85 Lymphedema studies recruiting now, 46 (54%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 22 · Phase 3 4 · Phase 4 4
First in 2001; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is close to the median of 50 across 369 interventional studies indexed under Lymphedema.
Median enrollment 50 across the 122 interventional studies, 148 across the 44 observational. Of the 114 that completed or were terminated, 39 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 168 have an industry lead sponsor. The 10 most frequent:
PureTech is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
PureTech has 1 study filed under Lymphedema — fewer than ten, so there is no comparison to draw.
13 of the studies in Lymphedema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05056207M.D. Anderson Cancer CenterPREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema | 2026-11-17 |
| NCT05825157Stanford UniversityEvaluation of Combination Therapy for Upper Extremity Lymphedema | 2027-01-01 |
| NCT02743858Memorial Sloan Kettering Cancer CenterLymphedema Surveillance Study | 2027-04 |
| NCT07012642Advanced Reconstructive Surgery AllianceEfficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema | 2027-04-09 |
| NCT05366699Stanford UniversityLYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy | 2027-06-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 168 studies in Lymphedema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema
This trial will utilize a randomised, double-blinded, placebo controlled design that will assess the safety, tolerability, and secondarily clinical efficacy of LYT-100 over a period of up to 6-months of dosing in breast carcinoma patients with secondary lymphoedema following sentinel lymph node biopsy and/or axillary node dissection, with or without radiation.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LYT-100 BID for 6 months
Drug: LYT-100 BCRL
Placebo BID for 6 months
Drug: Placebo BCRL
BCRL patients will receive LYT-100 BID for 6 months
Also known as: Deupirfenidone
BCRL patients will receive Placebo BID for 6 months
Also known as: Placebo
Safety and Tolerability: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Evaluate the safety and tolerability of LYT-100 as measured by TEAEs
Time frame: 6 months
| Milestone | LYT-100 in Patients With BCRL | Placebo in Patients With BCRL |
|---|---|---|
| Started | 28 | 22 |
| Completed | 10 | 7 |
| Not completed | 18 | 15 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Covid-19 lock down | 1 | 0 |
| Withdrew: Study terminated by sponsor | 11 | 12 |
Evaluate the safety and tolerability of LYT-100 as measured by TEAEs
| Participants | LYT-100 in Patients With BCRL | Placebo in Patients With BCRL |
|---|---|---|
| Safety and Tolerability: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 22 | 13 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LYT-100 in Patients With BCRL | 0/28 (0%) | 0/28 (0%) | 22/28 (78.6%) |
| Placebo in Patients With BCRL | 0/22 (0%) | 2/22 (9.1%) | 13/22 (59.1%) |
| Event | LYT-100 in Patients With BCRL | Placebo in Patients With BCRL |
|---|---|---|
| PyelonephritisInfections and infestations | 0/28 | 1/22 |
| Radius FractureInjury, poisoning and procedural complications | 0/28 | 1/22 |
| Event | LYT-100 in Patients With BCRL | Placebo in Patients With BCRL |
|---|---|---|
| NauseaGastrointestinal disorders | 13/28 | 2/22 |
| DiarrhoeaGastrointestinal disorders | 5/28 | 2/22 |
| DyspepsiaGastrointestinal disorders | 4/28 | 0/22 |
| COVID-19Infections and infestations | 4/28 | 1/22 |
| HeadacheNervous system disorders | 4/28 | 3/22 |
| FatigueGeneral disorders | 4/28 | 3/22 |
| InsomniaPsychiatric disorders | 3/28 | 0/22 |
| ConstipationGastrointestinal disorders | 2/28 | 2/22 |
| Urinary Tract InfectionInfections and infestations | 0/28 | 2/22 |
| DizzinessNervous system disorders | 0/28 | 2/22 |
| Age, Categorical(Participants) | LYT-100 in Patients With BCRL | Placebo in Patients With BCRL | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 18 | 39 |
| >=65 years | 7 | 4 | 11 |
| Sex: Female, Male(Participants) | LYT-100 in Patients With BCRL | Placebo in Patients With BCRL | Total |
|---|---|---|---|
| Female | 28 | 22 | 50 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | LYT-100 in Patients With BCRL | Placebo in Patients With BCRL | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 28 | 20 | 48 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | LYT-100 in Patients With BCRL | Placebo in Patients With BCRL | Total |
|---|---|---|---|
| United States | 9 | 9 | 18 |
| Australia | 19 | 13 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in Sep 2022, 30 months.
Results were first posted in Apr 2024, 1 year 7 months after primary completion. A results delay was requested in Sep 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone
PureTech